ARS Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, ARS Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $28.8. The average 1-year stock price forecast is 198.45% higher than the current stock price, while the lowest is $25 (+159.07%) and the highest is $32 (+231.61%).

Price Target: $28.8 (+198.45%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$28.8	$30	$32
Change	+159.07%	+198.45%	+210.88%	+231.61%

Analyst Ratings

The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	7	5	5
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	7	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lachlan Hanbury Brown William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 1, 2026
Joshua Schimmer Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $30	Buy	Maintains	$30	+210.88%	May 28, 2026
Carl Byrnes Northland Securities	Northland Securities	Buy Maintains $25	Buy	Maintains	$25	+159.07%	Apr 15, 2026
Kyle Bauser Roth MKM	Roth MKM	Buy Reiterates $30	Buy	Reiterates	$30	+210.88%	Apr 14, 2026
Ryan Deschner Raymond James	Raymond James	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jan 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

149.35M

from 84.28M

77.21%

from 84.28M

Revenue Next Year

273.65M

from 149.35M

83.23%

from 149.35M

EPS This Year

-1.76

from -1.74

EPS Next Year

-0.96

from -1.76

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	5.51M	1.32M	30.00K	89.15M	84.28M	149.35M
Revenue Growth	-69.13%	-76.10%	-97.72%	297,063.33%	-5.46%	77.21%
Gross Profit	-14.77M	-15.80M	-20.24M	68.59M	50.67M	112.16M
Gross Margin	-268.20%	-1,200.91%	-67,453.33%	76.94%	60.13%	75.10%
Operating Income	-19.45M	-34.46M	-67.52M	-3.08M	-179.45M	-198.80M
Net Income	-20.24M	-34.68M	-54.37M	8.00M	-171.30M	-179.35M
EPS	-	-	-	-	-1.74	-1.76
Free Cash Flow	-9.57M	-17.86M	-36.17M	16.50M	-94.59M	-160.86M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	161.6M
Avg	149.3M
Low	132.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	91.7%
Avg	77.2%
Low	57.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.76
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-